<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03602131</url>
  </required_header>
  <id_info>
    <org_study_id>ChiCGB-HR lymphomas</org_study_id>
    <nct_id>NCT03602131</nct_id>
  </id_info>
  <brief_title>Chidamide Combined With Clad/Gem/Bu With AutoSCT in High Risk Hodgkin &amp; Non-Hodgkin Lymphoma</brief_title>
  <official_title>Chidamide Combined With Cladribine/Gemcitabine/Busulfan (ChiCGB) With Autologous Stem-Cell Transplantation in High-risk Hodgkin and Non-Hodgkin Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sichuan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sichuan University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to explore the efficacy and safety of ChiCGB conditioning therapy in patients
      with high-risk Hodgkin and non-Hodgkin lymphoma.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2019</start_date>
  <completion_date type="Anticipated">March 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>2-year progression free survival</measure>
    <time_frame>2 years from recruitment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>2-year overall survival</measure>
    <time_frame>2 years from recruitment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment related mortality</measure>
    <time_frame>2 years from recruitment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>non-hematologic adverse events</measure>
    <time_frame>2 years from recruitment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Hodgkin Lymphoma</condition>
  <condition>Non-hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>ChiCGB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treated with chidamide, cladribine, gemcitabine and busulfan(ChiCGB) therapy followed by autologous hematopoietic stem cell transplantation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chidamide</intervention_name>
    <description>30 mg oral twice weekly for 2 weeks</description>
    <arm_group_label>ChiCGB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cladribine</intervention_name>
    <description>6 mg/m2 intravenously once daily for 5 days</description>
    <arm_group_label>ChiCGB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine</intervention_name>
    <description>2500 mg/m2 intravenously twice weekly for 1 week</description>
    <arm_group_label>ChiCGB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan</intervention_name>
    <description>3.2 mg/kg intravenously once daily for 4 days</description>
    <arm_group_label>ChiCGB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Autologous hematopoietic stem cell transplantation</intervention_name>
    <description>autologous hematopoietic stem cells infusion after ChiCGB chemotherapy</description>
    <arm_group_label>ChiCGB</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with primary refractory or recurrent diffuse large B cell lymphoma, mantle
             cell lymphoma, peripheral T cell lymphomas, Hodgkin lymphomas that do not qualify for
             treatment protocols of higher priority.

          -  Relapsed patients should respond to 2nd or 3rd line salvage chemotherapy and attain at
             least partial response before recruitment.

          -  Adequate renal function, as defined by estimated serum creatinine clearance &gt;/=50
             ml/min and/or serum creatinine &lt;/= 1.8 mg/dL.

          -  Adequate hepatic function, as defined by serum glutamate oxaloacetate transaminase
             (SGOT) and/or serum glutamate pyruvate transaminase (SGPT) &lt;/= 3 x upper limit of
             normal; serum bilirubin and alkaline phosphatase &lt;/= 2 x upper limit of normal.

          -  Adequate pulmonary function with forced expiratory volume at one second (FEV1), forced
             vital capacity (FVC) and diffusing capacity of lung for carbon monoxide (DLCO) &gt;/= 50%
             of expected corrected for hemoglobin.

          -  Adequate cardiac function with left ventricular ejection fraction &gt;/= 50%. No
             uncontrolled arrhythmias or symptomatic cardiac disease.

          -  Performance status 0-1. 10. Negative Beta diffusing capacity of the lung for carbon
             monoxide (HCG) text in a woman with child-bearing potential, defined as not
             post-menopausal for 12 months or no previous surgical sterilization

        Exclusion Criteria:

          -  Central nervous system lymphoma

          -  Patients relapsed after autologous stem cell transplantation

          -  Bone marrow was involved by lymphoma

          -  Patients with active hepatitis B or C(HBV DNA &gt;/=10,000 copies/mL).

          -  Active infection requiring parenteral antibiotics

          -  HIV infection, unless the patient is receiving effective antiretroviral therapy with
             undetectable viral load and a normal cluster of differentiation 4 (CD4) counts

          -  Evidence of either cirrhosis or stage 3-4 liver fibrosis in patients with chronic
             hepatitis C or positive hepatitis C serology.

          -  Patients with a corrected QT interval(QTc) longer than 500 ms
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>July 17, 2018</study_first_submitted>
  <study_first_submitted_qc>July 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2018</study_first_posted>
  <last_update_submitted>July 25, 2018</last_update_submitted>
  <last_update_submitted_qc>July 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sichuan University</investigator_affiliation>
    <investigator_full_name>Jie Ji</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>Chidamide</keyword>
  <keyword>autologous stem cell transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Cladribine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

